Top Markets
#1 ADO Protocol ADO Protocol +328.56%
#2 GoPlus Security GoPlus Security +54.62%
#3 Starpower Starpower +45.32%
#4 Nockchain Nockchain +37.41%
#5 Verus Coin Verus Coin +33.47%
#6 Tutorial Tutorial +33.44%
#7 GAIB AID GAIB AID +24.67%
#8 The Black Bull The Black Bull +24.62%
#9 Chainflip Chainflip +21.84%
#10 peaq peaq +20.16%
Coin of the day
ADO Protocol ADO Protocol
Innstillinger
Språk
NORSK
Valuta
USD
Tema
NuCana plc NuCana plc

NuCana plc

NCNA
Rangering i aksjer #32773
NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering... NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for advanced solid tumors, Phase Ib trials for both recurrent ovarian cancer and biliary tract cancer, a Phase II trial targeting platinum-resistant ovarian cancer, and a pivotal Phase III trial for pancreatic cancer. NuCana is also developing NUC-3373, a ProTide derivative of 5-fluorouracil’s active anti-cancer metabolite. This compound is currently in a Phase I study for advanced solid tumors and a Phase Ib/2 trial for advanced colorectal cancer. Additionally, NUC-7738, a nucleoside analog, is undergoing Phase 1/2 clinical assessment for both advanced solid and hematological malignancies. To support its ProTide technology development, the company maintains research, collaboration, and licensing agreements with Cardiff University and University College Cardiff Consultants Ltd., covering the design, synthesis, characterization, and assessment of these compounds. Further collaborative and licensing arrangements are in place with Cardiff ProTides Ltd. Established in 1997, the company operated as NuCana BioMed Limited before rebranding to NuCana plc in August 2017. Its corporate headquarters are located in Edinburgh, United Kingdom.
Aksjekurs
$1.51
Markedsverdi
$9.14M
Endring (1 dag)
-5.35%
Endring (1 år)
-59.65%
Land
GB
Handel NuCana plc (NCNA)

Kategori

Healthcare
Historikk for aksjesplitt for NuCana plc (NCNA)
Aksjen NuCana plc (symbol: NCNA) har gjennomgått totalt 0 aksjesplitt.
Den nyeste splittelsen skjedde Aug 17, 2026.
Én NCNA-aksje kjøpt før Aug 17, 2026 tilsvarer i dag 0 NCNA-aksjer.
Liste over aksjesplitt
År Splitt Multiplikator Kumulativ multiplikator
Ikke nok data for de angitte datoene.
Aksjesplitt for lignende selskaper eller konkurrenter
Selskap Antall aksjesplitt Kumulativ multiplikator Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 0 -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 0 -
BE